





Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa

### MAV+ Egypt

Last updated: February 2025

Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa. MAV+ is tightly aligned with African strategies and is supported by a broad and inclusive consortium of European actors.

Egypt is well-positioned to be a regional and continental hub for vaccine and biologicals manufacturing and export thanks to:

- A well-established industry with approximately 130 pharmaceutical sites
- A large domestic and export market
- A relatively strong regulatory authority, which achieved WHO's maturity level 3 for vaccine
- regulation in 2022


Furthermore, BioGeneric, an Egyptian private company, has been selected as a spoke for the EUD-funded mRNA vaccines hub, supporting the government's goal of advancing mRNA technology.

MAV+ support in Egypt aims to boost its regional impact by focusing on strategic planning, enhancing the capacities of manufacturing companies, and strengthening the regulatory authority. This support builds on the European Union and Egypt's long-lasting relationship and strengthened partnership under the European Neighbourhood Policy.

### **Key MAV+ collaborations and activities**

# Enhancing the capacities of Egyptian companies as a regional hub for vaccine and biologicals manufacturing and export

MAV+ is supporting the capacities of pharmaceutical R&D and manufacturing companies in reaching WHO Pre-Qualification Level for several products produced in their facilities. The new Special Measure announced in October 2023 will help increase the exposure of these products to different markets, including in Africa.







Medicines and Health Technologies in Africa

## Enhancing pharmaceutical strategies and regulations to support Egypt as a regional hub

As part of the new Special Measure announced in October 2023, MAV+ will also support:

- Developing a national strategy for vaccines and biologicals domestic production and export, in line with Egypt's ambition to become a regional hub. Such a strategy would cover licensing needs, manufacturing capacity, national demand, export needs, as well as competitiveness, among other areas. The strategy would allow the industry to better focus its efforts in these areas and would inform public policy, including those to foster a favorable ecosystem.
- Strengthening the capacities of the Egyptian Drug Authority (EDA) in different domains through a twinning project, including but not limited to the regulation of biologicals, extending the maturity of the agency to Level 4 and towards becoming a WHO listed authority. A twinning project will widen the recognition of EDA's decisions and approved products and help EDA in building regulatory harmonization on biologicals within Africa through the newly established African Medicines Agency.

### **Team Europe funders**

MAV+ actions in Egypt are primarily funded by the European Commission. Germany funds activities in Egypt as part of multi-country projects.

#### **Partners**

Partners for national projects include the Egyptian Drug Authority, Egyptian Ministry of Health and Population, Unified Purchasing Authority, Egyptian Federation of Industries (Chamber of Drug Industry) and public and private sector pharmaceutical companies). Egyptian Drug Authority is a key partner for multi-country projects.

### Additional Team Europe and international stakeholders

Stakeholders include BfArM (German Federal Insitute for Drugs and Medical Devices), Agence Française de Développement, (AFD), WHO, World Bank, Japan International Cooperation Agency (JICA) and International Labour Organisation (ILO).